• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share

NVAC Public Member: Ann Ginsberg, MD, PhD

NVAC Public Member | Term: 9/9/2015 – 9/9/2019 

Ann Ginsberg is Chief Medical Officer and a member of the Executive Office at Aeras, a not-for-profit, biotechnology organization developing improved tuberculosis (TB) vaccines for the world.  At Aeras, Dr. Ginsberg oversees all clinical activities and shares executive responsibility for the organization with the CEO and Chief Scientific Officer. She has been at Aeras since 2011.  From 2004 to 2011, Dr. Ginsberg was Head of Clinical Development and then Chief Medical Officer at the Global Alliance for TB Drug Development. From 2002 to 2004, she was Director, Project Management at Merck Research Laboratories. Dr. Ginsberg began her career in TB at the U.S. NIH, where she served in a number of positions, including Chief of the Respiratory Diseases Branch of the National Institute of Allergy and Infectious Diseases (NIAID).

Dr. Ginsberg has served on numerous global health advisory committees and is a former member of the Aeras Board of Directors.  She currently serves as a Consulting Editor for the journal Tuberculosis, is an ad hoc reviewer for a variety of peer-review journals, and has served as a member of several NIH Study Sections. Among other awards, she was the recipient of the Department of Health and Human Services Secretary’s Award for Distinguished Service in 2000.  Dr. Ginsberg is Board Certified in Anatomic Pathology and holds an AB from Harvard University, an MD from Columbia University, and a PhD in molecular biology from Washington University.

Content created by National Vaccine Program Office
Content last reviewed on March 22, 2016